The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

To evaluate the proportion of people who accept point-of-care testing among those offered testing.

Accepting testing

Time frame: Recruitment phase

To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested.

Prevalence

Time frame: Recruitment phase

To evaluate the HCV antibody prevalence among people tested.

Prevalence

Time frame: Recruitment phase

To evaluate the time to treatment uptake among people receiving point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment;

Time to treatment

Time frame: 52 weeks

To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.

Initiation of treatment

Time frame: 52 weeks

To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment following point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment;

Completion of treatment

Time frame: 52 weeks

To evaluate the proportion of participants who achieve an SVR following point-of-care HCV antibody testing with reflex HCV RNA testing in those who are HCV antibody detectable who received HCV treatment

SVR

Time frame: 52 weeks

To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.

HCV negative

Time frame: 52 weeks

To evaluate the cost of point-of-care HCV antibody testing prior to reflex HCV RNA testing compared to direct point-of-care HCV RNA testing and standard of care.

Cost-effectiveness

Time frame: 52 weeks